Cyted Appoints Martin Frost as Commercial and Strategic Advisor

Xenter, Inc. Appoints 4 Industry Leaders to Board of Directors; Closes $12M Series A

Xenter’s first product, which the company will announce shortly, is a medical device that not only combines the function of multiple existing devices but will also revolutionize the field of interventional medicine by producing valuable Physical Intelligence™ data and enabling advanced Artificial Intelligence solutions, leading to improved patient outcomes while reducing the cost, complexity and invasiveness of cardiac procedures.

Indivumed Partners with Oslo University Hospital to Advance Cancer Research

By scanning high-resolution images of haematoxylin and eosin-stained tumor section slides for all IndivuType cases, Indivumed will be able to leverage an entirely new dimension of data in the coming months.

Harold Hill Joins NeuX Technologies as Director of Corporate Accounts

Harold Hill is a retired Special Forces Medic, serving 26 years, and led the medical department for a Special Missions Unit within the United States Special Operations Command

September 29, 2020

Martin Frost has been appointed Commercial and Strategic Advisor of Cyted, Ltd.

Martin Frost will guide the Cyted team as the Company continues to grow and commercialise its products and services offering.

Martin has over 20 years of industry experience, including co-founding CMR Surgical in 2014. As CEO of CMR he was recognised as ‘UK Disruptor of the year’ in the 2019 Entrepreneur of the Year awards, and ‘Executive of the Year’ at the 2019 MedTech Insight awards, recognising his success in taking CMR from inception to global commercialisation with its surgical robot, Versius. To scale CMR, Martin raised over £250m, a record for any private European medical devices business.

Previously Martin has held a number of C-suite positions including CEO and CFO of Sagentia, the leading technology development company based in Cambridge, which he listed on the London Stock Exchange. Martin qualified as a Chartered Management Accountant, graduated from Cambridge University, and is Chair of the Peek Vision Foundation.

Cyted is enabling the earlier detection of disease, providing products and services that combine proprietary artificial intelligence technology and digital diagnostic infrastructure with next generation biomarkers. With significant expertise in pathology, the Company is developing a pipeline of digital and molecular tests for disease detection and risk stratification, to streamline diagnostic and clinical workflows. Cyted is initially focused on oesophageal cancer, where the combination of an identifiable at-risk population coupled with excellent therapy options offers a unique opportunity to improve patient outcomes through early detection.

Dr Will West, Chairman, Cyted, said: “Martin is a recognised commercial leader in successfully scaling technology and life science businesses. To have him involved at this stage of Cyted’s development is fantastic, as we embark on the next phase towards commercialisation.”

Martin Frost, Commercial and Strategic Advisor, Cyted, said: “What the team at Cyted has already achieved in terms of technical developments is impressive, and I look forward to working with Marcel and the Company as we continue to build strategic partnerships and move towards the commercialisation of Cyted’s products and services.”

Marcel Gehrung, CEO of Cyted, said: “Martin has an exceptional track record in the biotech, medtech and medical device development sectors and it is a privilege to welcome him to the team. With Martin’s help we plan to focus on the development of partnerships with NHS trusts, academic health networks and commercial groups, as well as continuing to expand the team at all levels.”



Subscribe to Medical Device News Magazine

Related Articles